Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + sacituzumab govitecan
- Development stage
- Phase 2
- Lead developer
- Akeso
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ivonescimab + sacituzumab govitecan is an investigational combination therapy being evaluated for the treatment of triple-negative breast cancer (TNBC), specifically in patients with brain metastases. Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), designed to combine immunotherapy with anti-angiogenesis. Sacituzumab govitecan is a TROP2-directed antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody conjugated to the topoisomerase I inhibitor SN-38. This combination aims to leverage the synergistic effects of immune checkpoint inhibition, anti-angiogenesis, and cytotoxic chemotherapy delivered via a targeted ADC to overcome resistance in advanced malignancies.
- Other names
- ivonescimab + TROP2 ADCAK112 + sacituzumab govitecanAK112 + IMMU-132ivoximab + TROP2 ADC
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + sacituzumab govitecan.